That deal is due to close towards the end of the year and, according to the three parties, Catalent will continue to operate independently and separately from Novo Holdings and Novo Nordisk
The outcome is a daily GLP-1 pill capable of suppressing appetite and improving metabolic markers without requiring injection
The most common issue is constipation, which can lead to straining and hard stools that put pressure on the rectal veins
"Novo Nordisk always puts patient safety first, and we urge all stakeholders, including the FDA, Boards of Pharmacy, and law enforcement, to take decisive action to uphold the highest quality standards of care." This one-time offer is intended to help patients who have previously been prescribed unapproved or illicit "semaglutide" drugs and are seeking access to authentic, FDA-approved Wegovy
Additionally, there is also the risk of contamination or improper dosing if the pharmacy is not reputable
Review your coverage options and talk with your healthcare provider to see what your best next steps are